PubRank

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 26944733)

Published in Europace on March 03, 2016

Authors

Michael D Ezekowitz1, John Eikelboom2, Jonas Oldgren3, Paul A Reilly4, Martina Brueckmann5, Anthony P Kent6, Janice Pogue2, Judith Spahr7, Andreas Clemens8, Herbert Noack8, Hans-Christoph Diener9, Lars Wallentin3, Salim Yusuf2, Stuart J Connolly2

Author Affiliations

1: Sidney Kimmel Medical College, Thomas Jefferson University, 1999 Sproul Rd., Broomall, Philadelphia, PA, USA Lankenau Medical Center, Wynnewood, PA, USA michael.ezekowitz@comcast.net.
2: Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
3: Department of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.
4: Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
5: Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
6: Sidney Kimmel Medical College, Thomas Jefferson University, 1999 Sproul Rd., Broomall, Philadelphia, PA, USA.
7: Lankenau Institute for Medical Research, Wynnewood, PA, USA.
8: Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany.
9: Department of Neurology, University Hospital Essen, Essen, Germany.

Associated clinical trials:

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate | NCT00262600

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial | NCT00808067

Articles citing this ↘

A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran. Cardiol Ther (2016) 0.75

Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord (2017) 0.75

Articles cited by this ↗

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med (1992) 9.71

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 3.09

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J (2009) 2.61

Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24

Articles by these authors ⇆

Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet (2016) 3.43

Sensible guidelines for the conduct of large randomized trials. Clin Trials (2008) 1.07

A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration. Int J Stroke (2015) 0.86

Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. J Headache Pain (2008) 0.84

Dabigatran etexilate and reduction in serum apolipoprotein B. Heart (2015) 0.83

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J (2017) 0.82

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J (2017) 0.81

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J (2017) 0.77

Atrial high-rate episodes and stroke prevention. Europace (2017) 0.75

Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE- Palestine. Confl Health (2017) 0.75

Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. J Am Coll Cardiol (2017) 0.75

Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design. Int J Stroke (2015) 0.75

Atrial high-rate episodes and stroke prevention. Europace (2016) 0.75

Failures, mistakes and shortcomings of my stroke trials. Cerebrovasc Dis (2013) 0.75